不同慢性鼻窦炎亚型的内镜鼻窦手术翻修率
该回顾性研究纳入2010-2015年由单一术者行内镜鼻窦手术的424例成人慢性鼻窦炎患者,分析不同亚型的翻修率。中位随访28个月时总体翻修率为4%,CRSwNP为3.5%,CRSsNP为5.1%;免疫缺陷和GPA患者翻修率较高,而AFS、AERD和EGPA较低。所有亚型术后SNOT-22评分均有临床意义的改善。
要点
- 总体翻修率4%,CRSwNP 3.5%,CRSsNP 5.1%。
- 免疫缺陷14%、GPA 40%翻修率较高,需优化管理。
- AFS、AERD、EGPA翻修率低,术后SNOT-22均改善。
核心结论
- 所有CRS亚型内镜鼻窦手术后SNOT-22评分均有临床意义的改善。
- 总体翻修率为4%,CRSwNP为3.5%。
- 免疫缺陷和GPA患者需要更多翻修手术,而AFS、AERD和EGPA翻修率低。
研究设计与样本
- 回顾性综述,纳入2010-2015年由单一术者行内镜鼻窦手术的成人CRS患者424例。
- CRSwNP 170例,CRSsNP 254例;309例(72.9%)无法具体分型,115例(27.1%)可具体分型。
主要发现
- 中位随访28个月(IQR 10-47个月),19例(4%)接受翻修ESS,其中CRSwNP 6例,CRSsNP 13例。
- CRSwNP和CRSsNP的翻修率分别为3.5%和5.1%。
- 亚型翻修率:AERD 2%、AFS 2%、免疫缺陷14%、GPA 40%、EGPA 0%、其他CRS 4%;中位随访时间分别为36、28、41、37、44和26个月。
关键数值与推荐
- 可具体分型者:AERD 47例(11.1%)、AFS 39例(9.2%)、免疫缺陷21例(5.0%)、GPA 5例(1.2%)、EGPA 3例(0.7%)。
临床怎么用
- 对免疫缺陷和GPA的CRSsNP患者应加强术后随访和优化治疗以降低翻修需求。
- 对AERD、AFS和EGPA患者,基于CRSwNP亚型的当代认识有助于制定手术和药物治疗策略。
局限性
- 回顾性研究设计。
- 单一术者操作,结果可能受术者经验影响。
- 多数患者(72.9%)无法具体分型,亚型分析样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Revision surgery rates following endoscopic sinus surgery (ESS) range between 7% and 50% and are influenced by many factors. This study investigates ESS outcomes for chronic rhinosinusitis (CRS) subtypes. METHODS: Retrospective review of adult CRS patients undergoing ESS with a single surgeon (2010-2015) was conducted. Outcomes were analyzed by CRS subtypes. RESULTS: ESS was performed in 424 CRS patients (CRS with nasal polyps [CRSwNP], n = 170; CRS without polyps [CRSsNP], n = 254). Most patients (309; 72.9%) could not be specifically subtyped; 115 (27.1%) were subtyped as follows: aspirin-exacerbated respiratory disease (AERD), n = 47 (11.1%); allergic fungal sinusitis (AFS), n = 39 (9.2%); immunodeficiency, n = 21 (5.0%); granulomatosis with polyangiitis (GPA), n = 5 (1.2%); and eosinophilic granulomatosis with polyangiitis (EGPA), n = 3 (0.7%). All subgroups experienced clinically meaningful reduction in postoperative 22-item Sino-Nasal Outcome Test (SNOT-22) scores. At median follow-up of 28 months (interquartile range [IQR], 10-47 months), 19 patients (4%) underwent revision ESS (CRSwNP, n = 6; CRSsNP, n = 13). Revision ESS rates were 3.5% and 5.1% for CRSwNP and CRSsNP, respectively. Revision ESS rate for subtypes were: AERD 2%; AFS 2%; immunodeficiency 14%; GPA 40%; EGPA 0%; and "all other CRS" 4% at median follow-up duration of 36, 28, 41, 37, 44, and 26 months, respectively. CONCLUSION: All CRS subtypes demonstrated clinically meaningful improvement in postoperative SNOT-22 scores following ESS. Our overall revision ESS rate was 4% (3.5% in CRSwNP). AFS, AERD, and EGPA groups demonstrated low revision rates, while immunodeficiency and GPA patients required more revision surgery. A contemporary understanding of CRSwNP subtypes facilitated surgical and medical strategies in improving outcomes for AERD, AFS, and EGPA patients. CRSsNP subtypes with immunodeficiency and GPA merit further investigation to optimize outcomes.
引用
- Miglani A, Divekar RD, Azar A, et al. Revision endoscopic sinus surgery rates by chronic rhinosinusitis subtype. Int Forum Allergy Rhinol. 2018. PMID: 29851243. doi:10.1002/alr.22146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。